On Thursday, October 30, the next session of the Santander Biomedical Lectures program will take place. On this occasion, Alexey V. Danilov will deliver a lecture entitled:
“Ubiquitin-proteasome system as a therapeutic target in hematologic malignancies.”
Alexey V. Danilov earned his medical degree in Russia and completed a hematology/oncology fellowship at Tufts Medical Center in Boston. He is a physician-scientist with training in molecular biology and cancer cell signaling, and experience in oncologic drug development. He leads an independent research program on B-cell malignancies that bridges the understanding of B-cell biology with early clinical evaluation of novel therapies.
As Director of the Early Therapeutics Program and Head of the Lymphoma Center, Dr. Danilov leads an experimental therapeutics initiative at City of Hope National Medical Center. His group’s preclinical focus centers on evaluating new targets within the ubiquitin-proteasome system and the oncogenic role of cyclin-dependent kinase 9. In addition, his team conducts correlative studies in multiple clinical trials. He has received funding from the National Cancer Institute (R01), the Leukemia & Lymphoma Society, the American Society of Hematology, and the Lymphoma Research Foundation. He also serves as Co-Chair of Translational Medicine for the Lymphoma Committee of the Southwest Oncology Group.
Clinically, Dr. Danilov is a practicing medical oncologist specializing in the care of patients with CLL and lymphoma. Building on his preclinical findings, he has launched multiple early-phase clinical trials with novel agents. As a member of industry committees and SWOG, and as leader of the Early Therapeutics Clinical Trials Network, he contributes to global drug development efforts.
The session will take place in the Téllez Plasencia Hall (Pavilion 16) at the Marqués de Valdecilla University Hospital on Thursday, October 30, at 8:15 a.m. No registration is required. Free admission until capacity is reached.
